We're thrilled to be expanding our operation to Devens and look forward to becoming a part of this exciting community filled ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations. The quarter's results, reaffirmed Bristol Myers Squibb's financial health and ...

Bristol Myers Squibb will cut $2 billion in costs by the end of 2027, a move aimed at long-term growth as the company prepares for patent expirations on key treatments, CNBC reported Feb. 6.

PRINCETON, N.J., January 31, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $57.42.